Cover Image

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report

Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease affecting over 71 million people worldwide. An increased incidence of atherothrombotic events [e.g. coronary artery disease (CAD), atrial fibrillation (AF)] has been observed in HCV seropositive patients. On the other hand...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mario Enrico Canonico (Author), Giuseppe Damiano Sanna (Author), Roberta Siciliano (Author), Fernando Scudiero (Author), Giovanni Esposito (Author), Guido Parodi (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON THE PROBLEM
by: Ekaterina S. Kropacheva
Published: (2018)

Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions
by: Marina Barakat, et al.
Published: (2022)

Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world
by: Sarah R. Donaldson, et al.
Published: (2022)

Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
by: Fagiuoli S, et al.
Published: (2023)

Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals
by: Zachary C. Rich, et al.
Published: (2016)

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
by: Nicola Imperatore, et al.
Published: (2017)

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
by: Saima Mushtaq, et al.
Published: (2022)

Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients
by: Grenda Leite Pereira, et al.
Published: (2019)

Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
by: Ramy H. Agwa, et al.
Published: (2022)

Drug-Induced Acute Pancreatitis in Adults: Focus on Antimicrobial and Antiviral Drugs, a Narrative Review
by: Angelo Del Gaudio, et al.
Published: (2023)

A study on the prevalence of HCV genotypes and the effect of direct-acting antiviral therapy on clinical and laboratory parameters in HCV-Infected patients at a tertiary care center in North India
by: S Muhammed Shahanas, et al.
Published: (2024)

An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs
by: Adita Ayu Permanasari, et al.
Published: (2021)

Access to free DAAs for people who inject drugs: is it sufficient to increase the update of HCV treatment by PWIDs?
by: Maka Gogia, et al.
Published: (2018)

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
by: Kimberly Struble, et al.
Published: (2019)

Management of patients taking antithrombotic drugs before dental surgery
by: Ju-Hsuan Yang, et al.
Published: (2020)

P28 Queensland injectors health network (QuIHN) treatment management program (TMP): hepatitis C virus (HCV) direct acting antivirals (DAA) full access for people who inject drugs
by: R. Kavanagh, et al.
Published: (2017)

Antiviral Drugs Intervention Strategies
Published: (2022)

Direct action antivirals are effective in the total eradication of HCV in renal transplants
by: Teresa Olea, et al.
Published: (2019)

Antiviral therapy of HCV-cirrhosis: case of sequential treatment and review of literature
by: Kakharman Yesmembetov, et al.
Published: (2018)

Current update on herbal sources of antithrombotic activity-a comprehensive review
by: Bhavani Subramani, et al.
Published: (2022)

Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery
by: Abdulaziz L, et al.
Published: (2022)

The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis
by: Ruochan Chen, et al.
Published: (2023)

P29 Treating hepatitis C virus infection (HCV) with direct acting antivirals (DAAs) through the existing infrastructure of opioid agonist therapy (OAT)
by: J. Keats, et al.
Published: (2017)

Antiviral Drugs Aspects of Clinical Use and Recent Advances
Published: (2012)

A critical evaluation of the process of drug discovery and evaluation: is the current approach the best possible one?
by: Enrico Garaci, et al.

Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, CanadaResearch in context
by: Dahn Jeong, et al.
Published: (2024)

Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry
by: Emma Gray, et al.
Published: (2017)

Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting
by: Elena Yela, et al.
Published: (2024)

Impact of drug use policy on the appropriate use of direct acting antiviral agents for Hepatitis C in Saudi Arabia
by: Ahmed Saqer Alotaibi, et al.
Published: (2021)

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
by: Tarek A Elshazly, et al.
Published: (2019)

Modelling the evolution of drug resistance in the presence of antiviral drugs
by: Archibald Chris, et al.
Published: (2007)

Synchronized separation of atorvastatinâan antihyperlipidemic drug with antihypertensive, antidiabetic, antithrombotic drugs by RP-LC for determination in combined formulations
by: M.V.N. Kumar Talluri, et al.
Published: (2012)

Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation
by: Manisha Pandey, et al.
Published: (2020)

Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy
by: Laura Camoni, et al.
Published: (2010)

Impact of HCV antiviral therapy on the Liver Transplantation Waiting-List assessed by mathematical models
by: Eleazar Chaib, et al.
Published: (2019)

SCORING MODELS FOR PREDICTING HEPATOCELLULAR CARCINOMA RISK IN HCV PATIENTS AFTER ANTIVIRAL THERAPY
by: Oana Irina Gavril, et al.
Published: (2023)

HCV-positive kidney transplant patients treated with direct-acting antivirals maintain stable medium-term graft function despite persistent reduction in tacrolimus trough levels
by: Maria Rendina, et al.
Published: (2022)

Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients
by: Reunanen Antti, et al.
Published: (2008)

Analysis of the consumption volumes of antithrombotic drugs used for pharmacotherapy of atrial fibrillation in Saratov Region
by: А. V. Sokolov, et al.
Published: (2022)

Potential antiviral properties of antifungal drugs
by: Falah H.O Al-Khikani, et al.
Published: (2020)